feeds

2018

This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization.

2018

These are the EMCDDA's final annual accounts for the financial year 2017.

25.06.2018
2018

The seventh European drugs summer school (EDSS) — ‘Illicit drugs in Europe: demand, supply and public policies’ — opens today in Lisbon on the eve of International day against drug abuse and illicit trafficking.

2018

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

2018

This report presents the top-level overview of the drug phenomenon in Estonia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

07.06.2018
2018

In a new update from the EU Early Warning System (EWS) on new psychoactive substances (NPS) (1), the EMCDDA releases today its latest insights in this area entitled Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation.

07.06.2018
2018

Evidence of increased cocaine availability is highlighted by the EMCDDA today in its European Drug Report 2018: Trends and Developments released in Brussels. The development occurs in the context of a dynamic drug market which is able to adapt rapidly in response to drug control measures.

2018

Country Drug Reports provide a top-level overview of the drug phenomenon in European countries, covering topics such as drug supply, drug use and public health problems as well as drug policy and responses. Each Country Drug Report focuses on a single country (28 EU Member States as well as Norway and Turkey, with which the EMCDDA has a special agreement) and is structured thematically. Individual sections are designed so that they may be read in isolation. Country Drug Reports are designed for online viewing but simple PDFs exist for each country.

2018

This report presents the top-level overview of the drug phenomenon in Poland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Lithuania, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Malta, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Cyprus, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Luxembourg, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2018

This report presents the top-level overview of the drug phenomenon in Finland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug situation in the United Kingdom, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in the Czech Republic, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Austria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Portugal, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Italy, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Sweden, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Slovenia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Slovakia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Croatia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Spain, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

The translated version was produced by the Spanish NFP.

2018

This report presents the top-level overview of the drug phenomenon in Greece, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Romania, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Bulgaria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Ireland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Latvia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

 

The translated version was produced by the Latvian NFP.

2018

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. This report covers the period from January 2016 until December 2017.

Loading